Skip to main content

H.U. Group Holdings, Inc. (MRCHF)

New York Stock Exchange Healthcare Medical - Diagnostics & ResearchView data quality →
57.7Fair

ValueMarkers Composite Index

Top 67%#14,834 of 44,722
Undervalued

72% below intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-3.00
Low Risk
Altman
1.59
Distress
DCF Value
$1
Undervalued
ROIC
1.4%
Low
P/E
31.4
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

H.U. Group Holdings, Inc. (MRCHF) — VMCI valuation read

H.U. Group Holdings, Inc. sits at VMCI 58/100, with the Healthcare sector median at 50. That 8-point spread is the first thing to note on MRCHF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on MRCHF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on MRCHF: MRCHF trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of -0.2x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

MRCHF rose 2.0% over the trailing 7 days, with a -16.6% read on a 30-day basis.

H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.

CEO: Shigekazu Takeuchi5,295 employeesJPwww.hugp.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.